Abstract
SARS-CoV-2 vaccine-induced antibodies are an immune correlate of protection against infection and are considered an appropriate metric to study susceptibility to infection.1 To date, studies of SARS-CoV-2 vaccine-induced antibody responses in patients with immune-mediated inflammatory diseases have only examined a few diagnoses and treatments, or only monitored participants for a short duration after vaccination. Moreover, few studies have addressed factors that modulate inter-individual antibody levels such as age,2 sex,2 vaccine modality,3 homologous or heterologous vaccination,4,5 time interval between vaccinations,4 infection before or after vaccination,6 and the infecting variant.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
